Axovant's IPO: Harbinger Of A Biotech Bubble?
This article was originally published in Start Up
Executive Summary
In June, Axovant Sciences Ltd. launched an IPO in which its stock almost doubled on the first day of trading and its valuation approached a frothy $3 billion. And this startling performance was attributed to just one asset – an experimental compound for Alzheimer’s disease.
You may also be interested in...
Axovant Closes Chapter On Failed, Second-Rate Small Molecule Strategy
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.
What's Next For Roivant? It's Not More Publicly Traded "Vants"
Roivant is focused on expanding its existing subsidiaries, building new ones and appointing top leadership teams to run them, but founder and CEO Vivek Ramaswamy has put a hold on more IPOs.
Defining Go And No-Go Disease Areas As An R&D Business
Some believe unmet need refers only to rare diseases and tiny patient populations. But it is more than this. In 2020, the term sits at the heart of decision-making for drug makers – along with cost, access and value, of course.
Need a specific report? 1000+ reports available
Buy Reports